Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 0 | NSE: VILINBIO | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Vilin Bio Med Ltd is a below average quality company.
The key valuation ratios of Vilin Bio Med Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Vilin Bio Med Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 4.9% | 4.5% | 3% | 12% | - |
| Value Creation Index ⓘ | -0.7 | -0.7 | -0.8 | -0.1 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||
| Sales ⓘ | 16.8 | 11.7 | 11.2 | 12.3 | 12 |
| Sales YoY Gr. | - | -30.3% | -4.4% | 9.8% | - |
| Adj EPS ⓘ | 0.4 | 0.3 | 0 | 1.3 | 0.9 |
| YoY Gr. | - | -16.7% | -86.7% | 3025% | - |
| BVPS (₹) ⓘ | 8.8 | 8.9 | 9 | 10.7 | 16.3 |
| Adj Net Profit ⓘ | 0.3 | 0.3 | 0 | 1.3 | 1 |
| Cash Flow from Ops. ⓘ | -1.5 | -1 | 0.2 | -1.7 | - |
| Debt/CF from Ops. ⓘ | -3.1 | -5.5 | 25.4 | -3 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | -9.9% | 9.8% | ||||
| Adj EPS ⓘ | NA | NA | 51.4% | 3025% | ||||
| BVPSⓘ | NA | NA | 6.9% | 19.6% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 4.1 | 3.4 | 0.5 | 13.8 | 6.6 |
| Op. Profit Mgn % ⓘ | 6.5 | 8.7 | 6.8 | 20.9 | NAN |
| Net Profit Mgn % ⓘ | 1.8 | 2.1 | 0.3 | 10.1 | 10.1 |
| Debt to Equity ⓘ | 0.6 | 0.8 | 0.7 | 0.5 | - |
| Working Cap Days ⓘ | 0 | 371 | 388 | 415 | 0 |
| Cash Conv. Cycle ⓘ | 0 | 252 | 296 | 268 | 0 |
Return on Equity has increased versus last 3 years average to 6.60%
Net Profit is growing at healthy rate in last 3 years 51.43%
Debt to equity has declined versus last 3 years average to 0.46
Sales growth has been subdued in last 3 years -9.86%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 0.9 | - |
| TTM Sales (₹ Cr.) | 12.3 | - |
| BVPS (₹.) ⓘ | 16.3 | - |
| Reserves (₹ Cr.) ⓘ | 9 | - |
| P/BV ⓘ | 1.29 | - |
| PE ⓘ | 23.53 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 29.3 |
| Equity (₹ Cr.) | 14 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 48.8 |
| Pledged * | 0.00 | 0.00 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|
| Sales | 16.81 | 11.72 | 11.21 | 12.31 |
| Operating Expenses ⓘ | 15.91 | 10.88 | 10.45 | 9.74 |
| Manufacturing Costs | 0.33 | 0.33 | 0.22 | 0.11 |
| Material Costs | 13.72 | 9.04 | 8.87 | 7.17 |
| Employee Cost | 1.20 | 0.91 | 0.85 | 0.78 |
| Other Costs ⓘ | 0.67 | 0.60 | 0.51 | 1.68 |
| Operating Profit ⓘ | 0.90 | 0.83 | 0.77 | 2.57 |
| Operating Profit Margin (%) | 5.3% | 7.1% | 6.8% | 20.9% |
| Other Income ⓘ | 0.01 | 0.03 | 0 | 0.02 |
| Interest ⓘ | 0.41 | 0.44 | 0.51 | 0.65 |
| Depreciation ⓘ | 0.31 | 0.26 | 0.22 | 0.17 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 0.19 | 0.16 | 0.04 | 1.78 |
| Tax ⓘ | 0.03 | 0.04 | 0.01 | 0.54 |
| Profit After Tax | 0.16 | 0.12 | 0.03 | 1.25 |
| PAT Margin (%) | 1.0% | 1.0% | 0.3% | 10.1% |
| Adjusted EPS (₹) | 0.2 | 0.2 | 0.0 | 1.3 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 7.24 | 7.36 | 7.40 | 10.68 | ||||||
| Share Capital ⓘ | 3.30 | 3.30 | 3.30 | 9.95 | ||||||
| Reserves ⓘ | 3.94 | 4.06 | 4.10 | 0.73 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | ||||||
| Debt | 4.53 | 5.52 | 5.30 | 4.93 | ||||||
| Long Term Debt | 0 | 1.02 | 0.73 | 0.43 | ||||||
| Short Term Debt | 4.53 | 4.50 | 4.57 | 4.50 | ||||||
| Trade Payables | 1.86 | 0.82 | 0.64 | 1.19 | ||||||
| Others Liabilities ⓘ | 0.37 | 0.20 | 0.22 | 0.89 | ||||||
| Total Liabilities ⓘ | 14.01 | 13.89 | 13.56 | 17.68 | ||||||
Fixed Assets | ||||||||||
| Gross Block | 2.13 | 1.87 | 9.36 | 9.38 | ||||||
| Accumulated Depreciation | 0 | 0 | 7.71 | 7.87 | ||||||
| Net Fixed Assetsⓘ | 2.13 | 1.87 | 1.65 | 1.51 | ||||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | ||||||
| Investmentsⓘ | 0 | 0 | 0 | 0 | ||||||
| Inventories | 2.11 | 2.06 | 2.28 | 0.88 | ||||||
| Trade Receivables | 7.27 | 7.65 | 7.79 | 9.87 | ||||||
| Cash Equivalents | 0.07 | 0.05 | 0.04 | 0.03 | ||||||
| Others Assetsⓘ | 2.43 | 2.27 | 1.80 | 5.38 | ||||||
| Total Assets ⓘ | 14.01 | 13.89 | 13.56 | 17.68 | ||||||
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -1.46 | -1 | 0.21 | -1.66 |
| PBT ⓘ | 0.19 | 0.16 | 0.04 | 1.78 |
| Adjustment ⓘ | 0.31 | 0.26 | 0.22 | 0.17 |
| Changes in Working Capital ⓘ | -1.93 | -1.38 | -0.05 | -3.07 |
| Tax Paid ⓘ | -0.04 | -0.04 | -0.01 | -0.54 |
| Cash Flow From Investing Activity ⓘ | -0.02 | 0 | 0 | -0.03 |
| Capex | -0.02 | 0 | 0 | -0.03 |
| Net Investments | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | 1.51 | 0.98 | -0.22 | 1.68 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 2.04 |
| Net Proceeds from Borrowing ⓘ | 0 | 1.02 | -0.28 | -0.29 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 |
| Others ⓘ | 1.51 | -0.03 | 0.07 | -0.07 |
| Net Cash Flow ⓘ | 0.03 | -0.02 | -0.01 | 0 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 2.24 | 1.66 | 0.46 | 13.78 | ||||||
| ROCE (%) | 5.09 | 4.89 | 4.31 | 17.17 | ||||||
| Asset Turnover Ratio | 1.2 | 0.84 | 0.82 | 0.79 | ||||||
| PAT to CFO Conversion(x) | -9.13 | -8.33 | 7 | -1.33 | Working Capital Days | |||||
| Receivable Days | 158 | 232 | 251 | 262 | ||||||
| Inventory Days | 46 | 65 | 71 | 47 | ||||||
| Payable Days | 49 | 54 | 30 | 47 | ||||||
The company was originally incorporated as a public limited company under the Companies Act, 1956 pursuant to a certificate of incorporation issued by the Registrar of Companies, Andhra Pradesh, Hyderabad dated June 29, 2005 with the name ‘Vilin Bio Med Limited’. It received a certificate of commencement of business on July 11, 2005 issued by Registrar of Companies, Andhra Pradesh, Hyderabad.
The company is engaged in domestic business of manufacturing Pharmaceuticals products and the Manufacturing Unit is located in Roorkee, in the State of Uttarakhand. In order to maintain its competitiveness and to further the cause of Healthcare, the company has laid a R&D Foundation and state of the art Manufacturing Facility in Roorkee. Its Sales Strategy is to sell its products in bulk to Pharmaceuticals Manufacturers, Marketers and Traders, who in turn provide the channel for sales to customers. Its products are primarily used by other pharmaceutical companies and traders, who ultimately will market it to the distributors and retail customers. It do not sell its products under any brand name.
Vilin Bio Med is engaged in the manufacturing of pharmaceuticals formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non Beta Lactam tablets and Capsules & Nutritional Food supplements. Its Promoters, Mr. Sadhanala Venkata Rao, Mr. Viswa Prasad Sadhanala, Mr. D. Srinivasa Reddy, and Mr. Anuj Bajpai are actively involved in the day-to-day business. Its Promoters are the guiding force behind the Strategic Decisions of the company. Their Industry Knowledge and understanding of the current market situation enables it to improve its geographic horizon and market presence.
Business area of the company
The company is engaged in the manufacturing of pharmaceuticals formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non Beta Lactam tablets and Capsules & Nutritional Food supplements.
Products of the company
History and milestone
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
